Literature DB >> 29150844

A phase I randomized controlled trial to evaluate safety and clinical effect of topically applied GSK2981278 ointment in a psoriasis plaque test.

E G Kang1, S Wu1, A Gupta1, Y-L von Mackensen2, H Siemetzki2, J M Freudenberg1, W Wigger-Alberti2, Y Yamaguchi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29150844     DOI： 10.1111/bjd.16131

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  7 in total

Review 1.  New Topical Therapies for Psoriasis.

Authors:  Ana Maria Lé; Tiago Torres
Journal:  Am J Clin Dermatol       Date:  2021-10-27       Impact factor: 7.403

Review 2.  (Inverse) Agonists of Retinoic Acid-Related Orphan Receptor γ: Regulation of Immune Responses, Inflammation, and Autoimmune Disease.

Authors:  Anton M Jetten; Donald N Cook
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-08-06       Impact factor: 13.820

3.  Blueprint for mechanistic, data-rich early phase clinical pharmacology studies in dermatology.

Authors:  Robert Rissmann; Matthijs Moerland; Martijn B A van Doorn
Journal:  Br J Clin Pharmacol       Date:  2020-04-06       Impact factor: 4.335

4.  Molecular Mechanism of Action of RORγt Agonists and Inverse Agonists: Insights from Molecular Dynamics Simulation.

Authors:  Nannan Sun; Congmin Yuan; Xiaojun Ma; Yonghui Wang; Xianfeng Gu; Wei Fu
Journal:  Molecules       Date:  2018-12-03       Impact factor: 4.411

5.  A Functional Variant rs3093023 in CCR6 Is Associated With IgA Nephropathy by Regulating Th17 Cells in a North Han Chinese Population.

Authors:  Yue-Miao Zhang; Xing-Zi Liu; Xu-Jie Zhou; Li-Jun Liu; Su-Fang Shi; Ping Hou; Ji-Cheng Lv; Hong Zhang
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

Review 6.  New Treatment Addressing the Pathogenesis of Psoriasis.

Authors:  Michio Tokuyama; Tomotaka Mabuchi
Journal:  Int J Mol Sci       Date:  2020-10-11       Impact factor: 5.923

7.  A phase I, randomized, double-blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF-06763809 in participants with mild-to-moderate plaque psoriasis.

Authors:  G Berstein; Y Zhang; Z Berger; E Kieras; G Li; A Samuel; T Yeoh; H Dowty; K Beaumont; W Wigger-Alberti; Y von Mackensen; U Kroencke; R Hamscho; S Garcet; J G Krueger; C Banfield; B Oemar
Journal:  Clin Exp Dermatol       Date:  2020-09-14       Impact factor: 3.470
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.